4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

RAP-219 Phase 2a trial in patients with drug-resistant focal onset seizures is fully enrolled and on track for topline results in September 2025Phase 2 trial of RAP-219 in bipolar mania has been initiated and is enrolling patients; trial remains on track, with topline results anticipated in the first half of 2027Ended the quarter with $260.4 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations through the end of 2026 BOSTON and SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and d

BOSTON and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today will host its inaugural Investor and Analyst Day, featuring presentations from Rapport's executive team on the Company's strategic priorities and updates from its clinical pipeline, including progress on the RAP-219 Phase 2a trial in focal epilepsy. The event's agenda also includes a fireside chat with key opinion leader and professor of Neurology at NYU Langone's Comprehensive Epileps

BOSTON and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences. Jefferies Global Healthcare Conference (New York City) - fireside chat on Wednesday, June 4, 2025, at 10:30 a.m. Eastern Time. Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Miami, FL) - fireside chat on Monday, June 9, 2025, at 10:00 a.m. Eastern Time. Interested parties may access the live and archived webc

BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced it will host its inaugural Investor and Analyst Day on Monday, June 2, 2025, in New York City. The event will also be webcast live. Rapport senior management will review the company's clinical programs, with a focus on the RAP-219 Phase 2a trial in refractory focal epilepsy. The event will also feature a fireside chat with Dr. Jacqueline A. French—a globally recognized leader in epilepsy research, profes

RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline results expected in the third quarter of 2025RAP-219 Phase 2a trial in patients with bipolar mania remains on track to commence in the third quarter of 2025, with topline results expected in the first half of 2027Company to host inaugural Investor and Analyst Day on June 2, 2025, featuring presentations from management team and key opinion leader Dr. Jacqueline FrenchEnded the quarter with $285.4 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations through the end of 2026 BOSTON and SAN DIEGO, May 08, 2025 (GLOBE NE

BOSTON and SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in three upcoming investor conferences. Jones Trading Virtual CNS Symposium - fireside chat on Tuesday, April 29, 2025, from 11:00-11:25am ET. Citizens JMP 2025 Life Sciences Conference (New York City) - fireside chat on Thursday, May 8, 2025, from 1:30-1:55pm ET. Mizuho Neuro & Ophthalmology Summit 2025 (New York City) - investor meet

BOSTON and SAN DIEGO, March 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced two encore poster presentations at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025, in San Diego, California. The data from these posters was originally presented at the American Epilepsy Society (AES) Annual Meeting in December 2024. The presentations will highlight the company's ongoing research and development of RA

Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027  Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer  Ended the year with $305.3 million in cash, cash equivalents, an

BOSTON and SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced the appointment of Dr. Jeffrey Sevigny as chief medical officer (CMO), effective immediately. A physician-scientist with more than 15 years of leadership in translational and clinical drug development, Dr. Sevigny has spearheaded groundbreaking research across neuroscience and rare diseases. His experience spans the full spectrum of development, from discovery to late-stage clinical trials an

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027  Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer  Ended the year with $305.3 million in cash, cash equivalents, an

BOSTON and SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced the appointment of Dr. Jeffrey Sevigny as chief medical officer (CMO), effective immediately. A physician-scientist with more than 15 years of leadership in translational and clinical drug development, Dr. Sevigny has spearheaded groundbreaking research across neuroscience and rare diseases. His experience spans the full spectrum of development, from discovery to late-stage clinical trials an

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing; topline data expected in Q1 2025Actively recruiting patients for Phase 2a trial of RAP-219 in focal epilepsy; trial on track and topline data expected in mid-2025 Investigational New Drug Application (IND) in diabetic peripheral neuropathic pain placed on clinical hold while the Company addresses U.S. Food and Drug Administration (FDA) Phase 2a trial protocol feedback Ended the quarter with $320.7 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is

SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

SC 13D - Rapport Therapeutics, Inc. (0002012593) (Subject)